Cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy and the value of markers for acute kidney injury
2024

Cytoreductive Surgery and Kidney Injury Markers

Sample size: 13 Editorial Evidence: low

Author Information

Author(s): Editorial Office of Asian Biomedicine

Primary Institution: Faculty of Medicine, Chulalongkorn University

Hypothesis

Can kidney biomarkers predict acute kidney injury in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy?

Conclusion

The study found that absolute measurements of kidney biomarkers cannot predict acute kidney injury in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Supporting Evidence

  • Systemic chemotherapy can cause acute kidney injury through various processes.
  • Kidney biomarkers can help predict kidney injury but have shown inconsistent results in cancer patients.
  • More studies are needed to confirm the relationship between surgery and kidney injury.

Takeaway

Doctors are trying to find better ways to tell if a patient's kidneys are hurt after surgery, but this study shows that the tests they used didn't work well.

Methodology

Patients were studied before and after surgery, with urine and blood samples taken to measure kidney biomarkers.

Limitations

The study had a small sample size and a low prevalence of acute kidney injury, which limits the findings.

Participant Demographics

Patients included those with gastric cancer (36.0%), ovarian cancer (30.7%), and colorectal cancer (22.7%), with varying prior chemotherapy exposure.

Digital Object Identifier (DOI)

10.2478/abm-2024-0032

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication